Evaxion to present three-year phase 2 EVX-01 melanoma vaccine efficacy data at ESMO 2026

PUBT · 1d ago
Evaxion to present three-year phase 2 EVX-01 melanoma vaccine efficacy data at ESMO 2026
  • Evaxion flagged a potential data catalyst at ESMO 2026, outlining plans to present three-year phase 2 efficacy results for EVX-01 in advanced melanoma.
  • Update includes extension-trial readout on durability of immune response, including third-year EVX-01 monotherapy outcomes following earlier combination use with Keytruda.
  • Prior two-year follow-up showed 75% objective response rate, including four complete responses; 92% of responders remained in response with no relapses.
  • Presentation scheduled for Oct. 24, 2026, in Madrid; abstract focuses on sustained T-cell responses with durable disease control.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607170715OMX_____CNEWS_EN_GNW1001213232_en) on July 17, 2026, and is solely responsible for the information contained therein.